[1] |
YANG Xin, YANG Baochun, YANG Yang, SHAO Huan.
One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
|
[2] |
LI Min, LI Chunlei, SUN Cuicui, YU Wenwen, SUN Qing, QI Yingmei, LIU Anchang.
One Case of Acute Generalized Exanthematous Pustulosis Caused by Abrocitinib Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 823-825.
|
[3] |
WANG Hongli, DU Juan, CAO Mengqi, ZHANG Luyong, JIANG Zhenzhou, HUANG Xin.
Effects of Triptolide on Secretion of Steroid Hormone in Primary Adrenocortical Cells
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 139-146.
|
[4] |
LIU Nannan, XI Yalin, CHEN Zhe.
One Case of Adrenocortical Insufficiency Caused by Cadonilimab
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.
|
[5] |
YU Wenlu, ZHANG Hong.
Research Progress in Applications of Strychnine Semen in Orthopedics and Traumatology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 116-120.
|
[6] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
[7] |
LIU Yadi, ZHANG Xiaomeng, CAI Haili, CHEN Siying, WANG Yu, ZHANG Bing.
Traditional Chinese medicine for prevention and treatment of adriamycin cardiotoxicity and an empirical study of evidence elements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 759-764.
|
[8] |
YU Xin, GONG Leilei, YAO Weijie, YUAN Sisi, FENG Xin.
Chinese patent medicines for recurrent spontaneous abortion: a scoping review of clinical evidence
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 361-365.
|
[9] |
JI Qiuxia, JIN Jian, ZHANG Bin.
Pharmaceutical care for immune-related adverse events induced by toripalimab
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
|
[10] |
ZHANG Zan, ZHANG Hui, HE Songhua, LUO Yi.
Four exogenously-polluted components in Tianwang Buxin pills analyzed via TLC and UPLC-QQQ-MS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 156-162.
|
[11] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[12] |
GUO Yijun, CHEN Xia, MENG Ping.
Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
|
[13] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[14] |
YIN Yuling, HU Chujuan, ZHANG Xiaomeng, WANG Yu, ZHANG Bing, LIN Zhijian.
Mining and validation of anti-adriamycin cardiotoxic effect of chicory extract
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 858-865.
|
[15] |
HE Xiong, MA Junlong, YANG Guoping.
Adverse events caused by HER2 conjugated antibodies via FAERS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.
|